OPKO Health competitors

Laurent Fischer joined Tobira's Board of Directors in April 2009 and became Chief Executive Officer in 2014. Laurent Fischer brings 20 years of drug development and commercialization experience in the biopharmaceutical industry. Prior to joining Tobira full time he was Chairman and Chief Executive Officer of Jennerex Inc., a private, clinical-stage biotherapeutics company focused on the design, development and commercialization of first-in-class, breakthrough targeted oncolytic immunotherapy products for cancer that was sold for up to $150 million. Prior to Jennerex, he was co-founder, president and CEO of Ocera Therapeutics (NASDAQ: OCRX), where he licensed and developed OCR-002 the first ammonia scavenger for the treatment of complications of liver disease and oversaw the approval of Zysa®, the first treatment approved for irritable bowel syndrome in Europe. Laurent Fischer has co-founded and managed four healthcare companies and held senior management positions at DuPont-Merck, DuPont Pharmaceuticals, and Hoffmann-La Roche in liver disease, virology and oncology. Laurent Fischer was responsible for the global launch of Sustiva® the first once-daily anti-HIV therapy, now part of the fixed dose combination therapy Atripla® and was involved in the launch of Invirase®, the first protease inhibitor, in the United States. Laurent Fischer received his undergraduate degree from the University of Geneva and his medical degree from the Geneva Medical School, Switzerland.

Ryan Spencer is a Board Member at Dynavax Technologies and Chief Executive Officer at Dynavax Technologies and is based in Berkeley, California. He has worked as Senior Director Commercial Operations at Dynavax Technologies; Senior Product Director, HEPLISAV-B at Dynavax Technologies; and Vice President, Corporate Strategy & Commercial Operations at Dynavax Technologies. Ryan attended Universidade Federal de Santa Catarina between 1995 and 1999.

J. David Hansen is a President & Chief Executive Officer at MABVAX THERAPEUTICS HOLDINGS, INC. and Board Member at MABVAX THERAPEUTICS HOLDINGS, INC..

Brad Gray joined NanoString from Genzyme Genetics, the diagnostic services division of Genzyme Corporation, where he was most recently Vice President of Product & Business Development leading the development of molecular diagnostics and partnering activities. Mr. Gray held several strategy and business development roles at the corporate and division levels beginning in 2004 when he joined Genzyme Corporation as Director of Corporate Development. Previously, Mr. Gray was a management consultant in the healthcare practice of McKinsey & Company. He holds a B.A. in Economics and Management from Oxford University, where he studied as a British Marshall Scholar, and an S.B. in Chemical Engineering from the Massachusetts Institute of Technology.

Richard Maradie is a Chief Executive Officer at NOVAVAX INC and is based in Rockville, Maryland.

Jon Cohen is a SVP at QUEST DIAGNOSTICS INC, Chief Executive Officer at Bioreference Laboratories, and Executive Chairman at Bioreference Laboratories and is based in Elmwood Park, New Jersey.